Telomir Pharmaceuticals Reports Promising Preclinical Data for Telomir-Zn in Wilson's Disease Model

Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research showing that its lead candidate, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson's disease model. The findings, which include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, support the biological activity of Telomir-Zn in this rare genetic disorder and expand the company's scientific validation.

Wilson's disease is a rare autosomal recessive disorder characterized by copper accumulation, primarily in the liver and brain, leading to hepatic and neurological symptoms. Current treatments include chelating agents and zinc therapy, but they often come with significant side effects and compliance issues. The preclinical study evaluated Telomir-Zn, a small molecule designed to modulate intracellular metal homeostasis and redox balance, in a well-established animal model of Wilson's disease.

Results showed that Telomir-Zn treatment led to a dose-dependent increase in survival rates, with the highest dose achieving near-complete survival compared to controls. Additionally, treated animals exhibited significantly reduced oxidative stress markers, lower hepatic copper levels, and improvements in liver enzyme levels indicative of better liver function. These effects were accompanied by modulation of genes involved in metal transport and antioxidant defense.

“The publication of these data in a peer-reviewed journal is a significant milestone for Telomir, as it provides independent validation of our platform's potential beyond oncology,” said Dr. Erez E. Scapa, CEO of Telomir Pharmaceuticals. “Wilson's disease represents a serious unmet medical need, and these results suggest Telomir-Zn could offer a novel therapeutic approach by targeting the underlying pathophysiology.”

The company is advancing its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation, and these new findings broaden the potential applications of Telomir-Zn. The study was conducted in collaboration with academic researchers and adds to a growing body of evidence supporting the compound's ability to address fundamental mechanisms implicated in aging and degenerative disease.

For more information, the full press release is available at https://ibn.fm/fOSNo.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic mechanisms in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, and genomic stability.